GOLDEN THROAT (06896) announced its annual results for the period ended December 31, 2025. The group recorded revenue of 943 million yuan, a decrease of 20.4% compared to the previous year. Profit attributable to owners of the parent company was 251 million yuan, down 21.16% year-on-year. Earnings per share were 33.98 fen, and the board proposed a final dividend of HK$0.34 per share. Moving forward, the group will be guided by consumer demand and will continue to optimize and enrich its product portfolio. It will further strengthen organizational capabilities, align resources around customer operations and digital marketing to enhance organizational effectiveness, establish a new growth strategy for GOLDEN THROAT products, and achieve healthy and sustainable development for the group. The company aims to continue consolidating its leading position in the throat lozenge market and to expand its market share in China's pharmaceutical and food sectors.